A recent initiative by the Cell Therapy Foundation (NYSEMKT:CTF) tabulating clinical trials involving cell therapy recently identified BHRT’s MyoCell as 1 of only a few cell therapies that are presently in the Phase III stage of clinical trials in the US. MyoCell has shown the ability to improve heart function in patients suffering from heart failure.
At the Heart Failure Society of America Annual Meeting, BHRT presented interim results from their randomized, double blinded, placebo controlled Phase II/III clinical trial called MARVEL. The MARVEL study focused on treating significant scar tissue damage caused from a previous heart attack in advanced heart failure patients. The results were outstanding with MyoCell treated patients improved 91.7 meters in the six minute walk test, while the placebo patients declined 4 meters.
BHRT’s MyoCell is a composition of immature myoblasts or adult muscle stem cells derived from a biopsy of a patient’s thigh muscle. This muscle biopsy is sent to BioHeart’s cGMP laboratory where the muscle stem cells are isolated and expanded. The cells are delivered directly into the scar tissue of the heart using BHRT’s MyoCath, a deflecting tip needle catheter. These stem cells may form contractile muscle in the scar tissue of damaged hearts.
Updating our 2/16/10 blog. The Cell Therapy Foundation strives to increase awareness about adult stem cells, to fund disease-specific adult stem cell research, and to accelerate the rate of clinical trials. www.celltherapyfoundation.org